NovaBay Pharmaceuticals, Inc. (formerly known as NovaCal Pharmaceuticals, Inc.) Provides Business Update and 2012 Outlook

EMERYVILLE, Calif., Feb. 9, 2012 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical-stage biotechnology company developing its first-in-class, anti-infective Aganocide® compounds for the topical non-systemic treatment and prevention of antibiotic-resistant infections, today provided a business update highlighting recent accomplishments and the Company's outlook for 2012.